Pathologic, cytogenetic and molecular assessment of acute promyelocytic leukemia (APL) patients treated with arsenic trioxide (As2O3,)

被引：0
|
作者：
Zhang, T [1 ]
Westervelt, P [1 ]
Hess, JL [1 ]
机构：
[1] Univ Washington, Sch Med, St Louis, MO USA
来源：
LABORATORY INVESTIGATION | 1999年 / 79卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
876
引用
收藏
页码：150A / 150A
页数：1
相关论文
共 50 条
  • [21] Clinical observation on the efficacy of all-trans retinoic acid (ATRA) combined with arsenic trioxide (As2O3) in newly diagnosed acute promyelocytic leukemia (APL).
    Liu, YF
    Shen, ZX
    Hu, J
    Zhu, YM
    Li, JM
    You, JH
    Shen, Y
    Shi, ZZ
    Chen, SJ
    Chen, Z
    Wang, ZY
    BLOOD, 2004, 104 (11) : 253A - 254A
  • [22] Arsenic trioxide (As2O3) induced selective apoptosis in acute promyelocytic leukemia (APL) cells involves a hydrogen peroxide (H2O2) dependent pathway.
    Jing, Y
    Dai, J
    Cohen, M
    Weinberg, RS
    Chalmers-Redmen, RME
    Tatton, WG
    Waxman, S
    BLOOD, 1998, 92 (10) : 595A - 595A
  • [23] Effect of additional cytogenetic abnormalities on survival in arsenic trioxide-treated acute promyelocytic leukemia
    Epstein-Peterson, Zachary D.
    Derkach, Andriy
    Geyer, Susan
    Mrozek, Krzysztof
    Kohlschmidt, Jessica
    Park, Jae H.
    Rajeeve, Sridevi
    Stein, Eytan M.
    Zhang, Yanming
    Iland, Harry
    Campbell, Lynda J.
    Larson, Richard A.
    Poire, Xavier
    Powell, Bayard L.
    Stock, Wendy
    Stone, Richard M.
    Tallman, Martin S.
    BLOOD ADVANCES, 2022, 6 (11) : 3433 - 3439
  • [24] Treatment of Molecular and Clinical Relapse of Acute Promyelocytic Leukemia (APL) with Arsenic Trioxide: Results of the European Registry of Relapsed APL
    Lengfelder, Eva
    Lo-Coco, Francesco
    Montesinos, Pau
    Grimwade, David
    Ades, Lionel
    Kishore, Bhuvan
    Pagoni, Maria
    Ramadan, Safaa M.
    Breccia, Massimo
    Holowiecka, Alexandra
    Pradel, Anne
    Sauerland, Maria Cristina
    Fenaux, Pierre
    Angel Sanz, Miguel
    BLOOD, 2010, 116 (21) : 12 - 12
  • [25] Clinical outcomes and rates of molecular remission with all-trans retinoic acid (ATRA) and arsenic trioxide (As2O3) combination therapy in newly diagnosed acute promyelocytic leukemia (APL).
    Tsirriberidou, A. M.
    Kantarjian, H. M.
    Garcia-Manero, G.
    Koller, C.
    Jones, D. M.
    Keating, M. J.
    Estey, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 337S - 337S
  • [26] Time course of arsenic species in red blood cells of acute promyelocytic leukemia (APL) patients treated with single agent arsenic trioxide
    Guo, Meihua
    Wang, Bin
    Liu, Shuchuan
    Wang, Wenjing
    Gao, Chunlu
    Hu, Shuang
    Fan, Shengjin
    Hai, Xin
    Zhou, Jin
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2019, 12 (04) : 371 - 378
  • [27] Exceptions in patterns of arsenic compounds in urine of acute promyelocytic leukaemia patients treated with As2O3
    Slejkovec, Zdenka
    Podgornik, Helena
    Cernelc, Peter
    Falnoga, Ingrid
    BIOMETALS, 2016, 29 (01) : 107 - 118
  • [28] Exceptions in patterns of arsenic compounds in urine of acute promyelocytic leukaemia patients treated with As2O3
    Zdenka Šlejkovec
    Helena Podgornik
    Peter Černelč
    Ingrid Falnoga
    BioMetals, 2016, 29 : 107 - 118
  • [29] Clinical study of combining arsenic trioxide (As2O3), all-trans retinoic acid (ATRA) and idarubicin (IDA) for induction therapy on the patients with relapsed acute promyelocytic leukemia(APL)
    Ma, J.
    Liu, J.
    Zhang, B.
    Zhan, Z.
    Jin, M.
    Wang, L.
    Gong, T.
    Shao, X.
    EJC SUPPLEMENTS, 2005, 3 (02): : 284 - 284
  • [30] Bone Marrow Findings in Patients with Acute Promyelocytic Leukemia Treated with Arsenic Trioxide
    Duffield, Amy
    Miller, Karin P.
    MODERN PATHOLOGY, 2018, 31 : 512 - 512
12345